Skip to content

To Estimate the Percentage of Children and Adolescents in Tunisia With Acceptably Controlled Diabetes Mellitus Type 1

Observational, Cross-sectional and Retrospective Study on Diabetes Mellitus Type 1 in Tunisian Children and Adolescents Under 15 Years

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01493388
Enrollment
402
Registered
2011-12-16
Start date
2012-03-31
Completion date
2012-07-31
Last updated
2017-01-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 1

Brief summary

This study is conducted in Africa. The aim of this study is to estimate the percentage of children and adolescents below or equal to 15 years in Tunisia with acceptably controlled diabetes mellitus type 1.

Interventions

DRUGinsulin

Patients will be treated according to routine clinical practice at the discretion of the treating physician.

Sponsors

Novo Nordisk A/S
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Written informed consent obtained before any study-related activities. (Study-related activities are any procedure related to recording of data according to the protocol). * Child or adolescent below or equal to 15 years with diabetes mellitus type 1 * Who has been undergoing treatment for diabetes for at least 6 months

Exclusion criteria

* Previous participation in this study. * Current participation to a clinical trial

Design outcomes

Primary

MeasureTime frame
Percentage of children below 6 years with HbA1c less than 8.5%one assessment during a 5 month period is made, by review of the patient's medical records and/or interview (only 1)
Percentage of children between 6-12 years with HbA1c less than 8%one assessment during a 5 month period is made, by review of the patient's medical records and/or interview (only 1)
Percentage of adolescents between 13 and 15 years with HbA1c less than 7.5%one assessment during a 5 month period is made, by review of the patient's medical records and/or interview (only 1)

Secondary

MeasureTime frame
Fasting plasma glucose (FPG) levelone assessment during a 5 month period is made, by review of the patient's medical records and/or interview (only 1)
Blood pressure level in children 12 years or olderone assessment during a 5 month period is made, by review of the patient's medical records and/or interview (only 1)
Total cholesterol and LDL-cholesterol levels in children 12 years or olderone assessment during a 5 month period is made, by review of the patient's medical records and/or interview (only 1)
Percentage of children with nephropathyone assessment during a 5 month period is made, by review of the patient's medical records and/or interview (only 1)
Percentage of children with self-monitoring of blood-glucoseone assessment during a 5 month period is made, by review of the patient's medical records and/or interview (only 1)
Percentage of parents and children having received at least one training and topic of the received trainingone assessment during a 5 month period is made, by review of the patient's medical records and/or interview (only 1)
Type and dose of insulin treatmentone assessment during a 5 month period is made, by review of the patient's medical records and/or interview (only 1)
Percentage of children with evaluation of thyroid function within the last 2 yearsone assessment during a 5 month period is made, by review of the patient's medical records and/or interview (only 1)
Percentage of children with microalbuminuriaone assessment during a 5 month period is made, by review of the patient's medical records and/or interview (only 1)
Percentage of children with hypoglycemia event having led to hospitalizationone assessment during a 5 month period is made, by review of the patient's medical records and/or interview (only 1)

Countries

Tunisia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026